Comprehensive Monograph: Desoximetasone (DB00547)

Executive Summary

Desoximetasone is a synthetic, high-potency, fluorinated topical corticosteroid engineered for its pronounced anti-inflammatory, anti-pruritic, and vasoconstrictive properties.[1] Classified pharmacologically as a Corticosteroid Hormone Receptor Agonist, its primary clinical application is in the management of corticosteroid-responsive dermatoses, including moderate-to-severe plaque psoriasis, atopic dermatitis, and eczema.[1] It is available in various formulations such as cream, ointment, gel, and spray, typically in strengths of 0.05% and 0.25%, allowing for therapeutic flexibility based on lesion type and location.[4]

The therapeutic efficacy of Desoximetasone is well-established, with clinical studies demonstrating its superiority over other corticosteroids like betamethasone valerate for certain indications.[6] However, its high potency necessitates a cautious approach to its use, as the therapeutic benefits are intrinsically linked to a significant risk profile. The principal safety concern is the potential for systemic absorption, particularly with use over large surface areas, on compromised skin barriers, for prolonged durations, or under occlusive dressings. Such absorption can lead to clinically significant systemic adverse effects, most notably reversible Hypothalamic-Pituitary-Adrenal (HPA) axis suppression, manifestations of Cushing's syndrome, hyperglycemia, and ocular complications such as glaucoma and cataracts.[7] Consequently, clinical guidelines strictly limit the duration of therapy, typically to four weeks or less, and emphasize careful patient selection and monitoring, especially in pediatric populations who are more susceptible to systemic toxicity.[10]

The regulatory landscape for Desoximetasone reveals a notable divergence between major markets. In the United States, the drug has a long history of approval by the Food and Drug Administration (FDA), with the brand name Topicort® and numerous generic products widely available.[12] In contrast, available data indicates that Desoximetasone is not currently registered with the Therapeutic Goods Administration (TGA) in Australia, making it unavailable through standard prescription channels in that country.[13] This report provides a comprehensive analysis of Desoximetasone, synthesizing its physicochemical properties, pharmacological profile, clinical applications, safety considerations, and global regulatory status to serve as a definitive resource for healthcare professionals, researchers, and regulatory specialists.

Section 1: Drug Identification and Physicochemical Properties

This section establishes the fundamental chemical and physical identity of Desoximetasone, providing a comprehensive catalog of its identifiers, structural characteristics, and properties. This foundational data is crucial for its unambiguous identification in research, clinical, and regulatory contexts.

1.1 Nomenclature and Identifiers

The standardized non-proprietary name for this small molecule is Desoximetasone. It is also known by several chemical synonyms, including Desoxymethasone, 17-Desoxymethasone, and Deoxydexamethasone, which reflect its structural relationship to other corticosteroids.[1] In the United States and Canada, it is most widely recognized by the brand name Topicort®.[4] To ensure precise identification across various scientific and regulatory databases, a comprehensive set of unique identifiers has been assigned to the molecule, as detailed in Table 1.

Table 1: Key Drug Identifiers for Desoximetasone

Identifier Type	Value	Source(s)
DrugBank ID	DB00547	1
CAS Number	382-67-2	1
UNII (Unique Ingredient Identifier)	4E07GXB7AU	1
European Community (EC) Number	206-845-3	1
PubChem Compound ID (CID)	5311067	18
ChEBI ID	CHEBI:691037	1
ChEMBL ID	CHEMBL1766	1
KEGG ID	D03697	1
ATC Code	D07AC03, D07XC02 (combinations)	4
RXCUI (RxNorm Concept Unique Identifier)	3255	1

These identifiers serve as a critical cross-referencing tool, allowing for the seamless integration of data from disparate sources. For instance, the CAS number used in chemical literature directly links to the rich pharmacological and clinical data contained within the DrugBank database, ensuring consistency and accuracy in research and practice.

1.2 Chemical Structure and Formula

Desoximetasone is a synthetic fluorinated steroid. Its molecular formula is C22​H29​FO4​, corresponding to a molecular weight of approximately 376.46 g/mol.[4]

The systematic IUPAC name for the compound is (8S,9R,10S,11S,13S,14S,16R,17S)-9-fluoro-11-hydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-7,8,11,12,14,15,16,17-octahydro-6H-cyclopenta[a]phenanthren-3-one.[1] For computational and database purposes, its structure is also represented by the following identifiers:

• InChI: InChI=1S/C22H29FO4/c1-12-8-16-15-5-4-13-9-14(25)6-7-21(13,3)22(15,23)18(27)10-20(16,2)19(12)17(26)11-24/h6-7,9,12,15-16,18-19,24,27H,4-5,8,10-11H2,1-3H3/t12-,15+,16+,18+,19-,20+,21+,22+/m1/s1 [1]
• InChIKey: VWVSBHGCDBMOOT-IIEHVVJPSA-N [1]
• SMILES: C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@@]4([C@]3([C@H](C[C@@]2([C@H]1C(=O)CO)C)O)F)C [1]

Structurally, Desoximetasone is a direct derivative of dexamethasone. The key modification that defines Desoximetasone is the substitution of the hydroxyl group at the 17-alpha position of dexamethasone with a hydrogen atom.[1] This seemingly minor structural change is fundamental to its pharmacological profile, influencing its potency and pharmacokinetic behavior. It is chemically classified as an 11beta-hydroxy steroid, a 21-hydroxy steroid, a 20-oxo steroid, a 3-oxo-Delta(1),Delta(4)-steroid, and a primary alpha-hydroxy ketone, reflecting the various functional groups and structural motifs within its complex steroidal backbone.[1]

1.3 Physical and Chemical Properties

In its solid state, Desoximetasone is described as an off-white solid or a white to practically white crystalline powder.[14] Its melting point is reported as a range between 206°C and 218°C.[20]

The solubility profile of Desoximetasone is characteristic of a lipophilic steroid. It is practically insoluble in water but is freely soluble in organic solvents such as chloroform and acetone.[20] Quantitative solubility data indicates good solubility in dimethylformamide (DMF) at 25 mg/mL, dimethyl sulfoxide (DMSO) at 30 mg/mL, and moderate solubility in ethanol at 3 mg/mL.[21] This lipophilicity is a critical property that facilitates its penetration through the stratum corneum of the skin, a necessary step for a topically administered drug to reach its site of action in the epidermis and dermis.

1.4 Crystal Structure Analysis

The precise three-dimensional arrangement of atoms in the solid state of Desoximetasone has been elucidated through X-ray crystallography. A study published in 1974 by Dupont, Dideberg, and Campsteyn provided a detailed analysis of its crystal structure.[1]

The analysis revealed that Desoximetasone crystallizes in an orthorhombic system, belonging to the Hermann-Mauguin space group P 21 21 21. The unit cell parameters were determined to be:

• a=11.319 A˚
• b=22.803 A˚
• c=7.381 A˚
• α=β=γ=90∘

The unit cell contains four molecules (Z=4).[1] The availability of such detailed crystallographic data from an early stage in the drug's history is significant. It demonstrates that the fundamental solid-state properties of the molecule have been well-characterized for decades. This foundational knowledge is essential for establishing robust quality control and manufacturing processes. A thorough understanding of the crystal structure is a prerequisite for ensuring batch-to-batch consistency of the active pharmaceutical ingredient (API), which is critical for maintaining the predictable efficacy and safety profile of all subsequent brand-name and generic formulations. This early characterization provides a high degree of confidence in the chemical integrity of the Desoximetasone used in clinical practice today.

Section 2: Comprehensive Pharmacological Profile

This section examines the molecular and physiological actions of Desoximetasone, detailing its mechanism of action, pharmacodynamic effects, and pharmacokinetic profile. This analysis provides the scientific basis for its therapeutic applications and associated risks.

2.1 Mechanism of Action: Molecular Pathways of Inflammation Suppression

Desoximetasone is a synthetic corticosteroid that exerts its therapeutic effects through potent glucocorticoid activity.[1] Its primary mechanism of action is as a Corticosteroid Hormone Receptor Agonist.[1] The process begins when the lipophilic Desoximetasone molecule diffuses across the cell membrane of target cells, such as keratinocytes and immune cells in the skin, and binds to specific intracellular glucocorticoid receptors.[22]

Upon binding, the receptor-steroid complex undergoes a conformational change, dissociates from chaperone proteins, and translocates into the cell nucleus.[22] Inside the nucleus, the complex acts as a ligand-dependent transcription factor. It binds to specific DNA sequences known as Glucocorticoid Response Elements (GREs) in the promoter regions of target genes, leading to the modulation of gene transcription. This can involve both the activation (transactivation) and repression (transrepression) of a wide array of genes.[22]

The cardinal anti-inflammatory effect of Desoximetasone is mediated through the transactivation of genes encoding anti-inflammatory proteins. A key outcome of this process is the induction of a family of proteins called lipocortins (also known as annexins).[7] These lipocortins exert their effect by inhibiting the enzyme phospholipase A2. Phospholipase A2 is a critical enzyme in the inflammatory cascade, responsible for cleaving arachidonic acid from membrane phospholipids.[22]

By preventing the release of arachidonic acid, Desoximetasone effectively shuts down the downstream synthesis of two major classes of pro-inflammatory mediators:

1. Prostaglandins: Synthesized via the cyclooxygenase (COX) pathway.
2. Leukotrienes: Synthesized via the lipoxygenase (LOX) pathway.

This blockade of the arachidonic acid cascade is the central molecular event that underlies the broad therapeutic actions of Desoximetasone, which include potent anti-inflammatory, anti-pruritic (anti-itch), and vasoconstrictive properties.[7] By depressing the formation, release, and activity of these and other mediators of inflammation (e.g., kinins, histamine), Desoximetasone effectively mitigates the clinical signs of dermatoses such as erythema (redness), edema (swelling), and pruritus (itching).[7]

2.2 Pharmacodynamics: Potency and Vasoconstrictive Activity

Desoximetasone is consistently classified as a high-potency or potent topical corticosteroid, placing it in the upper tier of agents used in dermatology.[9] Its pharmacodynamic activity has been characterized in various preclinical models, often in comparison to other well-known corticosteroids.

Animal studies provide valuable context for its relative potency. In a "Granuloma Patch Test" using croton oil to induce inflammation, Desoximetasone demonstrated activity comparable to that of dexamethasone.[24] When administered systemically (orally or subcutaneously) to rats, Desoximetasone was found to be approximately five times less potent than dexamethasone in inhibiting granuloma formation. However, when administered topically to rats, its potency was shown to be seven times greater than that of hydrocortisone and twice that of prednisolone.[24]

These comparative findings reveal a crucial aspect of its pharmacodynamic profile. The discrepancy between its relative potency in systemic versus topical administration models underscores the importance of formulation and percutaneous absorption in determining its clinical effect. While it may have a slightly lower intrinsic glucocorticoid activity than dexamethasone when bypassing the skin, its molecular structure and formulation are highly optimized for efficient penetration of the epidermal barrier and exertion of its effects locally within the skin. This demonstrates that the therapeutic utility of a topical steroid is not solely a function of its receptor binding affinity but is a complex interplay between its intrinsic pharmacodynamic activity and its pharmacokinetic behavior within the skin. Desoximetasone represents a successful optimization of these factors for topical application.

In clinical settings, a key surrogate marker for the potency and bioactivity of a topical corticosteroid is its ability to induce vasoconstriction in the skin, often referred to as the vasoconstrictor assay or skin blanching test. This effect is readily observable as a whitening of the skin at the application site. There is evidence to suggest a recognizable correlation between a drug's vasoconstrictor potency and its therapeutic efficacy in humans, and such assays are used to compare and predict the clinical potencies of different topical corticosteroids.[2] The high potency of Desoximetasone is reflected in its strong vasoconstrictive activity.

2.3 Pharmacokinetics: Absorption, Distribution, Metabolism, and Excretion (ADME)

The pharmacokinetic profile of Desoximetasone is defined by its behavior as a topically applied agent, where the primary goal is local action with minimal systemic exposure.

2.3.1 Factors Influencing Percutaneous Absorption

The extent to which Desoximetasone is absorbed through the skin (percutaneous absorption) is the most critical factor determining its potential for systemic side effects. This absorption is not a fixed value but is highly variable and influenced by multiple factors [2]:

• Vehicle Formulation: The cream, ointment, gel, or spray base in which the drug is formulated affects its release and penetration. Ointments, being the most occlusive, generally enhance penetration more than creams or gels.[25]
• Integrity of the Epidermal Barrier: Absorption is minimal through normal, intact skin. However, in inflammatory dermatoses where the skin barrier is compromised (e.g., in eczema or psoriasis), absorption is significantly increased.[2]
• Application Site: Absorption varies by anatomical location. Areas with a thin stratum corneum, such as the face, scrotum, and axilla, exhibit much higher absorption rates than areas with thick skin, like the palms and soles.
• Occlusion: The use of occlusive dressings (e.g., plastic wrap, adhesive bandages, or even tight-fitting diapers in infants) substantially increases percutaneous absorption.[2] This is the single most significant factor that can augment systemic exposure and is a primary driver of systemic toxicity.

2.3.2 Systemic Bioavailability and Half-Life

Once absorbed into the systemic circulation, Desoximetasone is handled via pharmacokinetic pathways similar to those of systemically administered corticosteroids.[2] It binds to plasma proteins to varying degrees, is primarily metabolized in the liver, and is subsequently excreted by the kidneys. A portion of the drug and its metabolites may also be excreted into the bile.[8] The predominant metabolic reaction involves conjugation to form glucuronide and sulfate esters, which are more water-soluble and easily excreted.[2]

Human pharmacokinetic studies using radiolabeled Desoximetasone have quantified its systemic absorption. One key study involving the application of 0.25% cream under occlusion for 24 hours found that total systemic absorption, as measured by excretion in urine and feces over seven days, was 5.2%±2.9% of the applied dose (4.1% in urine and 1.1% in feces).[2] Notably, blood levels of the drug remained below the limit of detection (0.005 µg/mL). A similar study with the 0.25% ointment formulation found an absorption extent of approximately 7%.[30]

While these absorption percentages may seem quantitatively low, their clinical significance is magnified by the drug's high potency. Even a small fraction of the applied dose, when absorbed systemically, is sufficient to exert powerful glucocorticoid effects throughout the body, leading to the potential for HPA axis suppression and other adverse events. This relationship between low absorption and high potency is central to understanding the drug's risk profile.

Furthermore, the elimination half-life of the absorbed material was determined to be relatively long, at 15±2 hours based on urinary excretion and 17±2 hours based on fecal excretion.[2] This extended half-life means that with the standard twice-daily application, there is a potential for systemic accumulation of the drug over the course of treatment. This cumulative exposure further elevates the risk of systemic toxicity, providing a strong pharmacokinetic rationale for the strict clinical recommendations to limit the duration of therapy.

Section 3: Clinical Efficacy and Therapeutic Applications

This section translates the fundamental pharmacology of Desoximetasone into its practical use in clinical medicine, outlining its approved indications, the evidence supporting its efficacy, and its strategic position within the therapeutic landscape of dermatology.

3.1 Approved Indications and Corticosteroid-Responsive Dermatoses

The primary, broadly defined indication for all formulations of Desoximetasone is for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.[2] This category encompasses a wide range of skin conditions characterized by inflammation and itching.

More specifically, Desoximetasone is prescribed for the treatment of [1]:

• Psoriasis: Particularly for managing the red, scaly patches characteristic of plaque psoriasis. The 0.25% topical spray is specifically indicated for the treatment of plaque psoriasis in adults.[5]
• Eczema (Dermatitis): Including various forms of eczema that cause dry, itchy, and inflamed skin.
• Atopic Dermatitis: A chronic, pruritic inflammatory skin disease.

Desoximetasone is generally considered most effective for acute or chronic dermatoses where a potent anti-inflammatory effect is required.[25] As a topical therapy, it is generally preferred over systemic corticosteroids for localized disease, as it controls the manifestations of the dermatosis while minimizing the risk of the more severe adverse effects associated with systemic administration.[25]

3.2 Clinical Evidence in Plaque Psoriasis and Atopic Dermatitis

The clinical efficacy of Desoximetasone is supported by decades of use and specific clinical studies. A clinical evaluation involving several hundred patients with various steroid-responsive dermatoses concluded that Desoximetasone 0.25% emollient cream was highly effective in both short-term and long-term comparative studies.[6]

A key comparative study directly evaluated Desoximetasone against another commonly used potent corticosteroid, betamethasone valerate. In this trial, Desoximetasone 0.25% emollient cream was found to be clinically superior to betamethasone valerate 0.1% cream in providing relief for the moderate and severe inflammatory manifestations of both psoriasis and atopic dermatitis.[6] This evidence helps to establish its position as a highly effective agent for these challenging conditions.

More recent clinical development has focused on newer formulations. Phase 2 clinical trials have been completed for the treatment of psoriasis, specifically investigating Desoximetasone spray at concentrations of 0.05% and 0.25%.[32] These studies, registered as NCT01018134 (a dose-ranging study) and NCT01043393 (an HPA axis safety study), underscore the ongoing research to optimize the delivery and safety of this potent molecule.[32]

3.3 Comparative Efficacy and Therapeutic Positioning

As a high-potency corticosteroid, Desoximetasone is not considered a first-line agent for mild or routine inflammatory skin conditions. Its therapeutic niche is in the management of moderate-to-severe or resistant dermatoses that have not responded adequately to lower-potency steroids.[2] The choice between the 0.25% and 0.05% strengths allows for some titration of potency, although both are considered potent agents.[25]

The clinical strategy for using Desoximetasone is often one of "step-down" therapy. It is employed to gain rapid initial control over a severe inflammatory flare-up. Once the condition has improved sufficiently, clinical guidelines recommend tapering the frequency of application (e.g., to every other day, then twice weekly) or transitioning to a less potent, and therefore safer, corticosteroid for long-term maintenance or for use on more sensitive skin areas.[28] This approach leverages the high efficacy of Desoximetasone for acute management while minimizing the cumulative exposure and the associated risks of long-term use, such as skin atrophy and HPA axis suppression.

This positions Desoximetasone as a crucial but typically transient tool in the dermatological armamentarium. It effectively bridges the therapeutic gap between milder topical treatments that may be insufficient for severe flares and systemic therapies (e.g., biologics, oral immunosuppressants), which carry their own distinct and significant risk profiles.

Section 4: Formulations, Dosage, and Administration

This section provides practical details on the clinical use of Desoximetasone, covering the commercially available products, recommended dosing regimens, and essential guidelines for proper administration to maximize efficacy and ensure patient safety.

4.1 Commercial Formulations and Strengths

Desoximetasone is available in a variety of topical formulations, allowing clinicians to select the most appropriate vehicle based on the characteristics of the skin lesion and the anatomical site being treated.[3] The primary strengths available are 0.25% and 0.05%.[8] The 0.25% formulations are classified as high-potency, while the 0.05% formulations are considered medium-to-high potency and are sometimes marketed with the "LP" (Low Potency) designation to distinguish them from the higher strength version.[4] The details of these formulations are summarized in Table 2.

Table 2: Summary of Available Formulations and Strengths of Desoximetasone (US Market)

Formulation	Available Strengths	Common US Brand Names	General Use Case / Vehicle Properties
Cream	0.25%, 0.05%	Topicort®, Topicort® LP, Generics	Emollient base, cosmetically elegant, suitable for a wide range of dermatoses, particularly in intertriginous areas. 4
Ointment	0.25%, 0.05%	Topicort®, Generics	Occlusive, lubricating base (e.g., mineral oil, petrolatum). Best for dry, lichenified, or scaly lesions. Provides enhanced penetration. 12
Gel	0.05%	Topicort®, Generics	Non-greasy, drying base. Useful for hairy areas like the scalp or for exudative (weeping) dermatoses. 12
Spray	0.25%	Topicort® Spray, Generics	Liquid formulation for application to larger surface areas or the scalp. Indicated specifically for plaque psoriasis. 5

The choice of formulation is a key clinical decision. For example, a patient with very dry, thickened psoriatic plaques would benefit most from the occlusive and hydrating properties of an ointment. In contrast, a patient with seborrheic dermatitis of the scalp would find a gel or spray formulation much more practical and cosmetically acceptable.

4.2 Dosing Regimens for Adults and Pediatric Patients

The standard dosing regimen for adults for all formulations of Desoximetasone is the application of a thin film to the affected skin areas twice daily.[3] It is important that the medication be rubbed in gently and completely. Therapy should be discontinued once control of the dermatosis is achieved. To mitigate the risk of local and systemic side effects, continuous treatment beyond four consecutive weeks is generally not recommended.[10]

For pediatric patients, the use of Desoximetasone requires increased caution. The general principle is to administer the least amount of the drug compatible with an effective therapeutic regimen for the shortest possible duration.[17] The safety and efficacy of all formulations have not been established in all pediatric age groups. For example, some product labeling specifies that the safety of the 0.25% ointment has not been established in children younger than 10 years of age.[25] Due to the heightened risk of systemic toxicity in children, use should be strictly supervised by a physician.

4.3 Administration Guidelines and Patient Counseling

Effective patient education is paramount to the safe use of Desoximetasone. Patients should receive the following instructions [2]:

• External Use Only: The medication is for application to the skin only. Contact with the eyes, mouth, or other mucous membranes must be avoided. It should not be used for any condition other than the one for which it was prescribed.
• Application Technique: Wash hands before and after application. Apply a small amount in a thin, even layer only to the affected areas and rub in gently.
• Avoid Sensitive Areas: Unless specifically directed by a physician, application to the face, groin, and axillae (armpits) should be avoided, as the thinner skin in these areas leads to increased absorption and a higher risk of local side effects like atrophy.
• No Unsupervised Occlusion: The treated skin area should not be bandaged, covered, or wrapped unless explicitly instructed by the physician. Parents of infants being treated in the diaper area should be advised not to use tight-fitting diapers or plastic pants, as these can act as occlusive dressings.
• Flammability Warning: The spray formulation is flammable. Patients should avoid heat, open flames, and smoking during and immediately after application.[7]
• Reporting Adverse Reactions: Patients should be instructed to report any signs of local adverse reactions (e.g., severe irritation, signs of infection, skin thinning) to their physician.

4.4 Use of Occlusive Dressings: Risks and Benefits

Occlusive dressings can be a valuable therapeutic adjunct to increase the penetration and efficacy of Desoximetasone, particularly for managing very thick, resistant, or lichenified dermatoses.[2] By trapping moisture and heat, occlusion hydrates the stratum corneum and dramatically enhances the percutaneous absorption of the corticosteroid.

However, this enhanced efficacy comes at the cost of a substantially increased risk of both local and systemic adverse effects.[2] Occlusion magnifies the potential for HPA axis suppression, skin atrophy, striae, and secondary infections (miliaria, folliculitis). Due to these significant risks, some sources explicitly state that Desoximetasone, as a potent corticosteroid, should not be used with occlusive dressings.[22] The use of occlusion with Desoximetasone should therefore be reserved for exceptional, resistant cases and must only be performed under the close supervision of an experienced physician, often for limited periods (e.g., 12 hours daily) and with careful monitoring for adverse effects.[25]

Section 5: Safety, Tolerability, and Risk Management

This section provides a comprehensive analysis of the safety profile of Desoximetasone. Owing to its high potency, a thorough understanding of its adverse effects, contraindications, and the necessary precautions for its use is essential for responsible clinical practice.

5.1 Profile of Adverse Effects

The adverse effects of Desoximetasone can be broadly categorized into local reactions at the site of application and systemic effects resulting from percutaneous absorption. The risk and severity of these effects are directly related to the potency of the steroid, the duration of use, the size of the treatment area, and the use of occlusion.

Table 3: Classification of Adverse Effects Associated with Topical Desoximetasone

System/Category	Adverse Effect	Frequency / Severity
Local Dermatologic (Common)	Burning, itching (pruritus), irritation, dryness, erythema	Common, particularly upon initial application; generally mild and transient. 11
Local Dermatologic (Long-Term/Occlusion-Related)	Skin atrophy (thinning, fragility, easy bruising), Striae (stretch marks), Telangiectasias (spider veins), Folliculitis, Acneiform eruptions, Perioral dermatitis, Hypopigmentation, Hypertrichosis (unwanted hair growth), Allergic contact dermatitis, Secondary infection (bacterial or fungal), Maceration of the skin, Miliaria (heat rash)	Less common but significant; risk increases with duration, potency, and occlusion. Some effects (atrophy, striae) may be irreversible. 7
Systemic Endocrine	Hypothalamic-Pituitary-Adrenal (HPA) axis suppression, Cushing's syndrome, Hyperglycemia, Glucosuria, Adrenal crisis (upon abrupt withdrawal)	Rare but most severe systemic risk. Associated with high doses, large surface area, prolonged use, occlusion, or use in children. 2
Systemic Ocular	Posterior subcapsular cataracts, Glaucoma (increased intraocular pressure)	Rare; risk associated with long-term use, especially around the eyes. 7
Systemic Pediatric-Specific	Linear growth retardation, Delayed weight gain, Intracranial hypertension (bulging fontanelles, headaches)	Significant risk in children due to higher surface area to body weight ratio. 3

5.1.1 Local Dermatological Reactions

The most frequently reported side effects are localized to the application site and include burning, itching, irritation, and dryness, which often occur when treatment is initiated and may resolve with continued use.[34] More concerning local reactions are typically associated with prolonged or inappropriate use. Skin atrophy is a hallmark of long-term potent steroid use and manifests as thin, fragile, transparent skin with easy bruising. Striae, which are permanent, are also a significant risk, particularly in intertriginous areas (e.g., groin, axillae) and on the face.[7]

5.1.2 Systemic Toxicity and HPA Axis Suppression

The most clinically significant risk of Desoximetasone is systemic toxicity resulting from percutaneous absorption. This can lead to the suppression of the HPA axis, a critical neuroendocrine system that regulates stress response and metabolism. Suppression can result in decreased endogenous cortisol production, and upon abrupt cessation of the topical steroid, can precipitate an adrenal crisis.[7] Chronic systemic exposure can produce manifestations of Cushing's syndrome, including weight gain (especially central), "moon face," slow wound healing, and muscle weakness.[7] Patients receiving large doses over extensive surface areas or under occlusion should be periodically evaluated for HPA axis suppression using laboratory tests like the urinary free cortisol test or ACTH stimulation test.[2]

5.1.3 Ocular Adverse Events

Although rare, the use of topical corticosteroids, particularly around the eyes, has been associated with an increased risk of developing posterior subcapsular cataracts and glaucoma.[7] Patients should be advised to avoid contact with the eyes and to report any visual symptoms, such as blurred vision, to their physician. An ophthalmologic evaluation may be warranted for patients on long-term therapy or those who develop visual changes.[7]

5.2 Contraindications and Hypersensitivity

The absolute contraindication for Desoximetasone is a known history of hypersensitivity to Desoximetasone or any of the inactive components within the specific cream, ointment, or gel formulation.[2]

Additionally, many sources cite relative contraindications or situations requiring extreme caution, including the presence of untreated cutaneous infections. Topical corticosteroids can suppress the local immune response, potentially masking the clinical signs of an infection or allowing it to worsen. Therefore, their use on untreated bacterial (e.g., impetigo), fungal (e.g., tinea), or viral (e.g., herpes simplex, varicella, vaccinia) lesions is generally contraindicated.[7] Allergic contact dermatitis to the corticosteroid itself can also occur, which may present paradoxically as a failure of the treated lesion to heal rather than as an acute exacerbation.[7]

5.3 Warnings, Precautions, and Special Populations

5.3.1 Pediatric Use and Growth Considerations

Pediatric patients are uniquely vulnerable to the systemic effects of topical corticosteroids. Their higher ratio of skin surface area to body weight leads to proportionally greater absorption of the drug compared to adults.[7] This places them at an increased risk for HPA axis suppression, Cushing's syndrome, and intracranial hypertension.[8] Chronic therapy poses a significant risk of interfering with normal growth and development, potentially causing linear growth retardation and delayed weight gain. Therefore, administration in children should be limited to the smallest effective amount for the shortest possible duration, and their growth should be monitored routinely.[3]

5.3.2 Use in Pregnancy and Lactation

Desoximetasone is classified as FDA Pregnancy Category C, indicating that animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in humans.[8] Animal studies have demonstrated that Desoximetasone is teratogenic and embryotoxic in mice, rats, and rabbits at doses ranging from 3 to 150 times the equivalent human dose.[11] Therefore, it should be used during pregnancy only if the potential benefit to the mother clearly justifies the potential risk to the fetus. Use on large areas, in large amounts, or for prolonged periods should be avoided.[28]

It is not known whether topical administration of Desoximetasone results in sufficient systemic absorption to produce detectable quantities in breast milk. While systemically administered corticosteroids are secreted into breast milk, the quantities are not typically considered harmful to the infant. Nevertheless, caution should be exercised when Desoximetasone is administered to a nursing woman.[8]

5.4 Overdose and Toxicity Management

An acute overdose of topically applied Desoximetasone is not expected to produce life-threatening symptoms.[41] However, chronic overuse or misuse (i.e., long-term application of high doses) can lead to the gradual onset of systemic corticosteroid toxicity, with symptoms as described above (e.g., thinning skin, easy bruising, signs of Cushing's syndrome).[22]

In the event of a significant accidental ingestion or suspected overdose, the national Poison Help hotline (1-800-222-1222) should be contacted for guidance.[41] Management of systemic corticosteroid toxicity is primarily supportive. It involves discontinuing the drug (often gradually, to prevent adrenal insufficiency), monitoring vital signs, and performing blood and urine tests to assess metabolic and electrolyte status. Specific symptoms are treated as they arise.[42]

Section 6: Drug and Disease State Interactions

This section evaluates the potential for Desoximetasone to interact with other medications and to be affected by or exacerbate co-morbid medical conditions. These interactions are primarily of clinical concern in scenarios where significant systemic absorption occurs.

6.1 Analysis of Potential Drug-Drug Interactions

For a topically applied medication like Desoximetasone, the risk of clinically significant systemic drug-drug interactions is generally low when used as directed (i.e., on limited surface areas for a short duration).[36] However, if systemic absorption becomes substantial due to misuse (e.g., prolonged application to large areas, use of occlusion), the drug will behave like a systemically administered corticosteroid, and a wide range of interactions become theoretically possible.

Databases list numerous potential interactions. For example, if absorbed systemically, Desoximetasone could [22]:

• Increase the risk of hyperglycemia when combined with oral antidiabetic agents (e.g., Acarbose, Acetohexamide).
• Increase the risk of adverse effects when combined with other immunosuppressive agents (e.g., Abatacept, Adalimumab, Anakinra).
• Increase the risk of hypokalemia when used with drugs like Albuterol or Amphotericin B.
• Decrease the bioavailability of Desoximetasone if used concurrently with antacids containing aluminum hydroxide or almasilate.

While this extensive list serves as an important cautionary framework, it primarily highlights the risks associated with inappropriate use that leads to high systemic exposure. For the typical patient using Desoximetasone correctly, these interactions are unlikely to be a major clinical issue.

The most practical and clinically relevant interaction is the additive effect with other corticosteroid-containing products. Patients should be explicitly warned not to use Desoximetasone concurrently with other topical, inhaled, or oral corticosteroids without first consulting their physician, as this will increase the total systemic steroid load and elevate the risk of HPA axis suppression and other systemic side effects.[8]

6.2 Considerations for Co-morbid Conditions

The presence of certain underlying medical conditions may increase the risks associated with Desoximetasone therapy, again primarily in the context of systemic absorption. There are five key disease state interactions to consider [43]:

• Diabetes Mellitus: Corticosteroids can induce hyperglycemia by promoting gluconeogenesis and insulin resistance. Systemic absorption of Desoximetasone may disrupt glycemic control in patients with diabetes, necessitating closer monitoring of blood glucose levels.[7]
• Skin Infections: Desoximetasone's immunosuppressive properties can mask the signs of a cutaneous infection or cause an existing infection to worsen. If a concomitant bacterial or fungal infection is present or develops, it must be treated with an appropriate antimicrobial agent. If the infection does not resolve promptly, Desoximetasone therapy should be discontinued until the infection is controlled.[2]
• Hyperadrenocorticism (Cushing's Syndrome): Patients with this pre-existing condition of excess cortisol should use Desoximetasone with extreme caution, as any systemic absorption will add to their already high glucocorticoid burden and can exacerbate the condition.[17]
• Ocular Toxicities: Patients with pre-existing glaucoma or cataracts should be monitored closely, as topical steroid use can increase intraocular pressure and hasten cataract formation.[7]
• Liver Failure: Since the liver is the primary site of corticosteroid metabolism, patients with hepatic dysfunction may have impaired clearance of absorbed Desoximetasone, potentially leading to higher systemic levels and an increased risk of HPA axis suppression.[9]

Section 7: Regulatory Status and Global Market Landscape

This section provides an overview of the regulatory approval and marketing status of Desoximetasone in key global markets, highlighting its availability, branding, and any notable regional differences in its regulatory standing.

7.1 United States FDA Approval History and Generic Availability

Desoximetasone has a long and well-established regulatory history in the United States. The brand name product, Topicort®, manufactured by Taro Pharmaceuticals, received its initial approvals from the U.S. Food and Drug Administration (FDA) several decades ago [12]:

• Cream (0.25%): Approved prior to January 1, 1982 (now discontinued).
• Gel (0.05%): Approved on March 29, 1982 (now discontinued).
• Ointment (0.25%): Approved on September 30, 1983 (now discontinued).
• Ointment (0.05%): Approved on January 17, 1985.
• Spray (0.25%): Approved on April 11, 2013.

Following the expiration of patents and marketing exclusivity, the FDA has approved numerous generic versions of Desoximetasone, fostering a competitive market. Generic approvals have been granted to various manufacturers, including Lupin, Perrigo, Padagis Israel, and The J Molner, for formulations such as the 0.05% ointment and the 0.25% spray.[12] In the US, all formulations of Desoximetasone are available by prescription only (Rx) and are not classified as controlled substances.[5] This history indicates that Desoximetasone is considered a mature, standard-of-care therapy within the US dermatological landscape, with both brand and lower-cost generic options readily available to patients.

7.2 Regulatory Status in Australia (TGA)

In stark contrast to its status in the United States, a review of the provided data indicates that Desoximetasone is likely not registered for supply in Australia. Searches of databases and documents related to the Australian Therapeutic Goods Administration (TGA) did not yield any product approvals for Desoximetasone or its common brand names like Topicort.[13] Instead, searches for related terms often returned information on Dexamethasone, which is a distinct, though structurally related, corticosteroid.[13]

This absence from the Australian Register of Therapeutic Goods (ARTG) is a significant finding with direct clinical implications. It means that Desoximetasone is not part of the standard therapeutic armamentarium for dermatologists in Australia. While Australian legislation provides pathways for accessing unregistered medicines, such as the Special Access Scheme (SAS), this process is reserved for cases with specific clinical justification and is far more complex than writing a standard prescription.[49] The practical consequence of this regulatory divergence is that Australian clinicians managing patients with severe, corticosteroid-responsive dermatoses must rely on alternative high-potency topical steroids that are registered with the TGA. This highlights a key difference in the available treatment algorithms between the US and Australian healthcare systems.

7.3 International Brand Names and Marketing

Desoximetasone is marketed under a wide array of brand names across the globe, reflecting its long history and widespread use in many countries. The specific brand name can vary significantly by region, which is an important consideration for medication reconciliation in a globalized healthcare environment. A selection of these international brand names is provided in Table 4.

Table 4: Selected International Brand Names for Desoximetasone by Country/Region

Country/Region	Brand Name(s)
United States	Topicort®, Topicort LP® 7
Canada	Desoxi, Taro-Desoximetasone, Topicort Mild 17
France, Belgium, Morocco	Topicorte 7
Germany, Austria, Switzerland, South Africa	Topisolon 7
Brazil, Ecuador, Peru, Uruguay	Esperson 7
United Arab Emirates, Finland, Kuwait, Netherlands, Norway, Saudi Arabia, Sweden	Ibaril 7
Indonesia	Dercason, Desomex, Desoxiron, Dexigen, Dexocort, Inerson, Topcort 7
South Korea	Demetason, Deoxone, Derapasone, Metapason 7
Thailand	Desoxi, Dexocort, T.o.cort, Topoxy 7
Taiwan	Chemin, Desosone, Dexison, Uson 7

This list is not exhaustive but illustrates the diverse branding of the same active pharmaceutical ingredient worldwide. The name Topicort, while dominant in North America, is used alongside many other local and regional brand names.

Section 8: Expert Analysis and Concluding Remarks

This final section synthesizes the comprehensive data presented in this monograph to provide an expert analysis of Desoximetasone's overall therapeutic profile, offer recommendations for its clinical use, and reflect on its position in contemporary dermatologic practice.

8.1 Synthesis of Desoximetasone's Risk-Benefit Profile

The clinical profile of Desoximetasone is best understood as a balance between high efficacy and significant risk, a characteristic common to potent therapeutic agents. Its high potency is a "double-edged sword." The primary benefit of Desoximetasone lies in its robust and rapid anti-inflammatory and anti-pruritic activity, which makes it highly effective for gaining control over moderate-to-severe or recalcitrant inflammatory dermatoses. Clinical evidence confirms its superiority over less potent agents for conditions like psoriasis and atopic dermatitis, providing a valuable tool for managing acute disease flares that significantly impact a patient's quality of life.[6]

Conversely, the principal risk is directly tied to this same high potency. The potential for local and systemic adverse effects is substantial and well-documented. Locally, the risk of irreversible skin atrophy and striae with long-term use is a major concern that limits its chronic application, especially on sensitive areas.[7] Systemically, the risk of HPA axis suppression is the most critical safety issue. The pharmacokinetic data, which shows that even a small percentage of absorbed drug can have profound systemic effects due to its high intrinsic activity and long half-life, underscores this risk.[2]

Therefore, the risk-benefit calculation for Desoximetasone is highly conditional. The balance is favorable only when the drug is used appropriately: for a clear and severe indication, over a limited body surface area, for the shortest possible duration, and with strict avoidance of unsupervised occlusion. When these clinical principles are violated, the risk of significant harm can easily outweigh the therapeutic benefit.

8.2 Recommendations for Clinical Practice and Monitoring

Based on the synthesized evidence, the following recommendations are provided to guide the safe and effective clinical use of Desoximetasone:

1. Patient Selection: Reserve Desoximetasone for moderate-to-severe corticosteroid-responsive dermatoses that have failed to respond to lower-potency topical steroids. It should not be used as a first-line agent for mild conditions.
2. Therapeutic Strategy: Employ Desoximetasone primarily for short-term "rescue" or induction therapy to control acute flares. The treatment plan should include a clear "step-down" strategy, involving tapering the frequency of application or transitioning to a less potent agent once clinical control is achieved. Continuous therapy beyond four weeks is strongly discouraged.[10]
3. Patient Education: Comprehensive patient counseling is the cornerstone of safe use. Instructions must emphasize the application of a thin film only to affected areas, avoidance of sensitive sites like the face and groin, the dangers of unsupervised occlusion, and the importance of adhering to the prescribed duration of therapy.[2]
4. Clinical Monitoring:

• Regularly assess the clinical response. If no improvement is seen within 2-4 weeks, the diagnosis and treatment plan should be re-evaluated.[3]
• At each follow-up visit, examine the treated skin for early signs of local adverse effects, particularly atrophy, striae, or secondary infection.
• In high-risk scenarios (e.g., treatment of a large surface area, prolonged use, or in pediatric patients), maintain a high index of suspicion for systemic effects. Monitor for signs of Cushing's syndrome and, in children, routinely track growth parameters.[7]

8.3 Future Perspectives and Unmet Needs

Desoximetasone was developed and approved in an era when potent topical corticosteroids were a mainstay of dermatologic therapy. In the 21st century, the treatment landscape for severe inflammatory skin diseases like psoriasis and atopic dermatitis has been revolutionized by the advent of targeted biologic agents and small molecule inhibitors (e.g., JAK inhibitors). These systemic therapies offer novel mechanisms of action that can provide profound and lasting disease control.

Despite these advances, potent topical steroids like Desoximetasone retain an essential and enduring role. They remain indispensable for the rapid, effective management of localized disease flares, even in patients on systemic therapy. Their ability to quickly reduce inflammation and pruritus provides immediate symptomatic relief that is highly valued by patients.

An unmet need in the field is the development of topical agents that can dissociate the potent anti-inflammatory effects of glucocorticoids from their atrophogenic and systemic side effects. Future research may focus on novel formulations that optimize drug delivery to target cells within the skin while further minimizing systemic absorption, or on the development of "soft steroids" that are rapidly metabolized to inactive forms upon entering the systemic circulation. The regulatory divergence between major markets like the US and Australia also highlights ongoing challenges in global drug access and the need for greater harmonization of regulatory standards for established, effective medicines.

Works cited

1. Desoximetasone | C22H29FO4 | CID 5311067 - PubChem, accessed September 27, 2025, https://pubchem.ncbi.nlm.nih.gov/compound/Desoximetasone
2. DESOXIMETASONE CREAM USP, 0.25% - DailyMed, accessed September 27, 2025, https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=4ad6c159-4daa-4a33-8db6-351b5263323d
3. Desoximetasone Topical: MedlinePlus Drug Information, accessed September 27, 2025, https://medlineplus.gov/druginfo/meds/a605026.html
4. Desoximetasone - brand name list from Drugs.com, accessed September 27, 2025, https://www.drugs.com/ingredient/desoximetasone.html
5. Desoximetasone (Topicort): Uses, Side Effects, Alternatives & More - GoodRx, accessed September 27, 2025, https://www.goodrx.com/desoximetasone/what-is
6. Desoximetasone--a new topical corticosteroid: short- and long-term experiences - PubMed, accessed September 27, 2025, https://pubmed.ncbi.nlm.nih.gov/344003/
7. Desoximetasone | Drug Lookup | Pediatric Care Online - AAP Publications, accessed September 27, 2025, https://publications.aap.org/pediatriccare/drug-monograph/18/5023/Desoximetasone
8. Desoximetasone Cream USP, 0.05%, Cream USP, 0.25 ... - DailyMed, accessed September 27, 2025, https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=4f4fc43f-bcd5-4f98-bafc-20db6207c603
9. Topicort (desoximetasone) dosing, indications, interactions, adverse effects, and more, accessed September 27, 2025, https://reference.medscape.com/drug/topicort-desoximetasone-343655
10. Desoximetasone Topical Dosage Guide + Max Dose, Adjustments ..., accessed September 27, 2025, https://www.drugs.com/dosage/desoximetasone-topical.html
11. Safety Data Sheet Desoximetasone Cream USP Strength: 0.25% Pack Size, accessed September 27, 2025, https://vionausa.com/wp-content/uploads/2021/01/Desoximetasone-Cream-USP-0.25-SDS.pdf
12. Generic Topicort Availability - Drugs.com, accessed September 27, 2025, https://www.drugs.com/availability/generic-topicort.html
13. DEXAMETHASONE JUNO (Juno Pharmaceuticals Pty Ltd ..., accessed September 27, 2025, https://www.tga.gov.au/resources/prescription-medicines-registrations/dexamethasone-juno-juno-pharmaceuticals-pty-ltd
14. Desoximetasone | 382-67-2 - ChemicalBook, accessed September 27, 2025, https://www.chemicalbook.com/ChemicalProductProperty_EN_CB0346960.htm
15. CAS No : 382-67-2 | Product Name : Dexamethasone - Impurity F | Chemical Name : 9-Fluoro-11β,21-dihydroxy-16α-methylpregna-1,4-diene-3,20-dione | Pharmaffiliates, accessed September 27, 2025, https://www.pharmaffiliates.com/en/382-67-2-dexamethasone-impurity-f-pa0451060.html
16. What is Desoximetasone Topical? - Columbia Doctors, accessed September 27, 2025, https://www.columbiadoctors.org/health-library/drug-info/desoximetasone-topical/
17. Desoximetasone (topical application route) - Side effects & dosage - Mayo Clinic, accessed September 27, 2025, https://www.mayoclinic.org/drugs-supplements/desoximetasone-topical-application-route/description/drg-20073760
18. Desoximetasone - Wikipedia, accessed September 27, 2025, https://en.wikipedia.org/wiki/Desoximetasone
19. Desoximetasone | CAS 382-67-2 | SCBT - Santa Cruz Biotechnology, accessed September 27, 2025, https://www.scbt.com/p/desoximetasone-382-67-2
20. PRODUCT MONOGRAPH TOPICORT® (desoximetasone cream, USP, 0.25%), accessed September 27, 2025, https://pdf.hres.ca/dpd_pm/00015890.PDF
21. Desoximetasone (A 41-304, 17-deoxy Dexamethasone, HOE 304, CAS Number: 382-67-2), accessed September 27, 2025, https://www.caymanchem.com/product/23945/desoximetasone
22. Desoximetasone: Uses, Interactions, Mechanism of Action | DrugBank Online, accessed September 27, 2025, https://go.drugbank.com/drugs/DB00547
23. publications.aap.org, accessed September 27, 2025, https://publications.aap.org/pediatriccare/drug-monograph/18/5023/Desoximetasone#:~:text=Mechanism%20of%20Action&text=May%20depress%20the%20formation%2C%20release,the%20release%20of%20arachidonic%20acid.
24. PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION PrDESOXI Desoximetasone Cream, USP Cream, 0.05% w/w and 0.25% w/w, To, accessed September 27, 2025, https://pdf.hres.ca/dpd_pm/00072458.PDF
25. Desoximetasone Monograph for Professionals - Drugs.com, accessed September 27, 2025, https://www.drugs.com/monograph/desoximetasone.html
26. Label: DESOXIMETASONE cream - DailyMed, accessed September 27, 2025, https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4ad6c159-4daa-4a33-8db6-351b5263323d
27. Desoximetasone Cream USP, 0.25% - DailyMed, accessed September 27, 2025, https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=309a93de-ce89-4244-959a-3236d5e95c06
28. Topicort - Drug Summary - PDR.Net, accessed September 27, 2025, https://www.pdr.net/drug-summary/Topicort-Ointment-0-25--desoximetasone-1613
29. Topicort (Desoximetasone) Ointment USP 0.05% For topical use only. Not for oral, ophthalmic, or intravaginal use. Rx only DESCRI - accessdata.fda.gov, accessed September 27, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/018594s007lbl.pdf
30. Desoximetasone Ointment USP, 0.25%For topical use only. Not for oral, ophthalmic or intravaginal use.Rx only - DailyMed, accessed September 27, 2025, https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=bcbc8163-dcf7-458f-a470-1e1a2edf2cc7&type=display
31. TOPICORT® topical spray - accessdata.fda.gov, accessed September 27, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/204141s009lbl.pdf
32. Desoximetasone Completed Phase 2 Trials for Psoriasis Treatment | DrugBank Online, accessed September 27, 2025, https://go.drugbank.com/drugs/DB00547/clinical_trials?conditions=DBCOND0013339&phase=2&purpose=treatment&status=completed
33. Topicort® Gel - accessdata.fda.gov, accessed September 27, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/18586slr004_topicort_lbl.pdf
34. Side Effects of Topicort (desoximetasone): Interactions & Warnings - MedicineNet, accessed September 27, 2025, https://www.medicinenet.com/side_effects_of_topicort_desoximetasone/side-effects.htm
35. Desoximetasone Topical Side Effects: Common, Severe, Long Term, accessed September 27, 2025, https://www.drugs.com/sfx/desoximetasone-topical-side-effects.html
36. Desoximetasone topical Uses, Side Effects & Warnings - Drugs.com, accessed September 27, 2025, https://www.drugs.com/mtm/desoximetasone-topical.html
37. Desoximetasone Cream: Package Insert / Prescribing Info - Drugs.com, accessed September 27, 2025, https://www.drugs.com/pro/desoximetasone-cream.html
38. Desoximetasone | Davis's Drug Guide for Rehabilitation Professionals, accessed September 27, 2025, https://fadavispt.mhmedical.com/content.aspx?bookid=1873§ionid=139007743
39. Desoximetasone Generic Ointment - RxList, accessed September 27, 2025, https://www.rxlist.com/desoximetasone-generic-drug.htm
40. FDA - FDA, accessed September 27, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/074286Orig1s017lbl.pdf
41. desoximetasone topical - MyActiveHealth, accessed September 27, 2025, https://www.myactivehealth.com/hwcontent/content/multum/d01291a1.html
42. Corticosteroids overdose: MedlinePlus Medical Encyclopedia, accessed September 27, 2025, https://medlineplus.gov/ency/article/002582.htm
43. Topicort LP Interactions Checker - Drugs.com, accessed September 27, 2025, https://www.drugs.com/drug-interactions/desoximetasone-topical,topicort-lp.html
44. Desoximetasone topical Interactions - Drugs.com, accessed September 27, 2025, https://www.drugs.com/drug-interactions/desoximetasone-topical.html
45. Lupin Receives FDA Approval for Generic Topicort® LP Emollient Cream, 0.05% and Topicort® Cream, 0.25%, accessed September 27, 2025, https://www.lupin.com/lupin-receives-fda-approval-for-generic-topicort-lp-emollient-cream-0-05-and-topicort-cream-0-25/
46. Perrigo Company Announces FDA Approval for Desoximetasone Gel - Jan 10, 2006, accessed September 27, 2025, https://investor.perrigo.com/2006-01-10-Perrigo-Company-Announces-FDA-Approval-for-Desoximetasone-Gel
47. Therapeutic Goods Administration (TGA) | Australian Government Department of Health, Disability and Ageing, accessed September 27, 2025, https://www.tga.gov.au/
48. Australian Public Assessment Report for Dexamethasone - Therapeutic Goods Administration (TGA), accessed September 27, 2025, https://www.tga.gov.au/sites/default/files/auspar-dexamethasone-161025.pdf
49. Access to unregistered drugs in Australia - Australian Prescriber - Therapeutic Guidelines, accessed September 27, 2025, https://australianprescriber.tg.org.au/articles/access-to-unregistered-drugs-in-australia.html